Skip to content
OKUROnKure Therapeutics, Inc.

Earnings

When OnKure Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

Mar 11, after the close

Thu, Mar 11, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 8 – Apr 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$13.50M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$17.85MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release2.7%by the close of Nov 5
    Revenue
    —
    —
    Net income
    -$17.85M
    N/M
    EPS
    -$0.36
    N/M
    On November 4, 2026, OnKure Therapeutics, Inc. issued a press release reporting financial results for the quarter ended September 30, 2026.
  2. Q2 2026Aug 4, 2026, after the closeThe release+1.5%by the close of Aug 5
    Revenue
    —
    —
    Net income
    -$15.35M
    N/M
    EPS
    -$0.31
    N/M
  3. Q1 2026May 5, 2026, after the closeThe release10.4%by the close of May 6
    Revenue
    —
    —
    Net income
    -$15.16M
    N/M
    EPS
    -$1.11
    N/M
  4. Q4 2025Mar 12, 2026, after the closeThe release+7.5%by the close of Mar 13
    Revenue
    —
    —
    Net income
    -$13.50M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q——-$0.362.7%
Q2 2026Jun 30, 2026Aug 4, 2026 · after-hoursAug 4, 202635 d10-Q——-$0.31+1.5%
Q1 2026Mar 31, 2026May 5, 2026 · after-hoursMay 5, 202635 d10-Q——-$1.1110.4%
FY 2025
Q4 2025Dec 31, 2025Mar 12, 2026 · after-hoursMar 12, 202671 d10-K———+7.5%
Q3 2025Sep 30, 2025Nov 6, 2025 · after-hoursNov 6, 202537 d10-Q——-$1.094.1%
Q2 2025Jun 30, 2025Aug 12, 2025 · after-hoursAug 12, 202543 d10-Q——-$1.14+20.0%
Q1 2025Mar 31, 2025May 5, 2025 · after-hoursMay 6, 202536 d10-Q——-$1.1910.8%
FY 2024
Q4 2024Dec 31, 2024Mar 10, 2025 · after-hoursMar 10, 202569 d10-K———+1.0%
Q3 2024Sep 30, 2024—Nov 7, 202438 d10-Q——-$36.55+1.0%
Q2 2024Jun 30, 2024Aug 13, 2024 · after-hoursAug 13, 202444 d10-Q——-$44.82—
Q1 2024Mar 31, 2024May 7, 2024 · after-hoursMay 7, 202437 d10-Q——-$30.37—
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026447202
10-QAug 4, 2026332773
10-QMay 5, 2026206345
10-KMar 12, 2026104147
10-QNov 6, 2025269540
10-QAug 12, 2025178981
10-QMay 6, 2025063970
10-KMar 10, 2025036252
10-QNov 7, 2024123233
10-QAug 13, 2024096411

Provenance

ProvenanceData status and checks

OnKure Therapeutics, Inc. · CIK 1637715 · Engraved from SEC EDGAR